BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12538453)

  • 1. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
    Wasenius VM; Hemmer S; Kettunen E; Knuutila S; Franssila K; Joensuu H
    Clin Cancer Res; 2003 Jan; 9(1):68-75. PubMed ID: 12538453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
    Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
    J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression and role of serum response factor in papillary carcinoma of the thyroid.
    Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
    Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
    Kebebew E; Peng M; Reiff E; Duh QY; Clark OH; McMillan A
    Surgery; 2005 Dec; 138(6):1102-9; discussion 1109-10. PubMed ID: 16360397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro.
    Bigelow RL; Williams BJ; Carroll JL; Daves LK; Cardelli JA
    Breast Cancer Res Treat; 2009 Sep; 117(1):31-44. PubMed ID: 18787947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression in poorly differentiated papillary thyroid carcinomas.
    Fluge Ø; Bruland O; Akslen LA; Lillehaug JR; Varhaug JE
    Thyroid; 2006 Feb; 16(2):161-75. PubMed ID: 16676402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
    Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
    BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications.
    Jarzab B; Wiench M; Fujarewicz K; Simek K; Jarzab M; Oczko-Wojciechowska M; Wloch J; Czarniecka A; Chmielik E; Lange D; Pawlaczek A; Szpak S; Gubala E; Swierniak A
    Cancer Res; 2005 Feb; 65(4):1587-97. PubMed ID: 15735049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression and the biological phenotype of papillary thyroid carcinomas.
    Delys L; Detours V; Franc B; Thomas G; Bogdanova T; Tronko M; Libert F; Dumont JE; Maenhaut C
    Oncogene; 2007 Dec; 26(57):7894-903. PubMed ID: 17621275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
    Dahl E; Kristiansen G; Gottlob K; Klaman I; Ebner E; Hinzmann B; Hermann K; Pilarsky C; Dürst M; Klinkhammer-Schalke M; Blaszyk H; Knuechel R; Hartmann A; Rosenthal A; Wild PJ
    Clin Cancer Res; 2006 Jul; 12(13):3950-60. PubMed ID: 16818692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
    Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
    J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
    Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
    Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
    Murphy KM; Chen F; Clark DP
    Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profile of malignant and non-malignant diseases of the thyroid gland reveals altered expression of a common set of genes in goiter and papillary carcinomas.
    Stolf BS; Abreu CM; Mahler-Araújo MB; Dellamano M; Martins WK; de Carvalho MB; Curado MP; Díaz JP; Fabri A; Brentani H; Carvalho AF; Soares FA; Kowalski LP; Hirata R; Reis LF
    Cancer Lett; 2005 Sep; 227(1):59-73. PubMed ID: 16051032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of differentially expressed genes in human autosomal dominant polycystic kidney tissue].
    Zhuang WL; Wu YM; Ge SY; Mei CL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Dec; 22(6):705-8. PubMed ID: 16331579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
    O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
    Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of (-)-epigallocatechin-3-gallate on expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in fibroblasts irradiated with ultraviolet A.
    Song XZ; Xia JP; Bi ZG
    Chin Med J (Engl); 2004 Dec; 117(12):1838-41. PubMed ID: 15603715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
    Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
    Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium.
    Obokata A; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Kuramoto H
    Anticancer Res; 2007; 27(1A):95-105. PubMed ID: 17352221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.